E-MAIL: your-email@mail.com
E-MAIL: your-email@mail.com
India’s drug regulator, CDSCO, clears Takeda’s recombinant live attenuated dengue vaccine for prevention of dengue in individuals aged 4–60 years.
imphoenix82
Under the agreement, Insilico will lead the AI-driven discovery process to identify molecules that meet predefined scientific and early development criteria, while Takeda will leverage its global development capabilities to advance selected candidates through clinical validation.
imphoenix82HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.
Contact: +91 9354115542
HealthXploreIndia @2026. All Rights Reserved.
